Biotech · Private company
OncoC4, Inc.
Track this companyFree. Adds OncoC4, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials88 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- DocetaxelPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- GotistobartPhase 3 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GotistobartPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- AI-081Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- lutetium Lu 177 vipivotide tetraxetanPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONC-392Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONC-392Phase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONC-392 highPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONC-392 lowPhase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONC-783Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ONC-841Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid TumorsPHASE1 · RECRUITING · started Aug 10, 2026ClinicalTrials.gov NCT07408258 · fetched Nov 12, 2026
- Gotistobart Long Term Extension (LTE) StudyPHASE3 · ENROLLING_BY_INVITATION · started Jul 28, 2026ClinicalTrials.gov NCT07659379 · fetched Nov 12, 2026
- Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Mar 26, 2025ClinicalTrials.gov NCT06635785 · fetched Nov 12, 2026
- Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid TumorsPHASE1 · RECRUITING · started Aug 23, 2024ClinicalTrials.gov NCT06352359 · fetched Nov 12, 2026
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 11, 2023ClinicalTrials.gov NCT05682443 · fetched Nov 12, 2026
- ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 28, 2023ClinicalTrials.gov NCT05671510 · fetched Nov 12, 2026
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 22, 2022ClinicalTrials.gov NCT05446298 · fetched Nov 12, 2026
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 16, 2020ClinicalTrials.gov NCT04140526 · fetched Nov 12, 2026